Isomorphic Labs raises $5 billion to move its drug candidates toward clinical trials
Isomorphic Labs, an AI drug-discovery company spun out of Google DeepMind in 2021, has closed a $5 billion Series C round. The money is meant to help take its drug candidates into clinical trials and further develop its technology.

Isomorphic Labs, an AI drug-discovery company that was spun out of Google's AI lab DeepMind in 2021, announced on 17 November that it has raised $5 billion in a Series C funding round. The company wants to move its drug candidates into clinical trials, making the raise one of the largest in the AI-driven drug-development sector.
The round was co-led by investment firms Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, alongside others. All existing backers also participated, including Alphabet's venture arms GV and Capital G, as well as Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
How the platform works
Isomorphic Labs is building an AI drug-design engine. It relies on a range of simulation models that explore different areas of chemistry to help design medicines. The company's work builds on DeepMind's AlphaFold model, which predicts the three-dimensional structure of proteins from their genetic sequence alone. The company says its programme has produced "positive preclinical results" in oncology and immunology. It has signed deals with pharmaceutical giants Eli Lilly, Novartis and Johnson & Johnson.
Use of the funds
The new money follows a $2.1 billion Series B round in May. It will go toward continued development of the drug-design engine and toward expanding into more types of medicine.
The Series C is the company's first fundraise since its founder and CEO, Demis Hassabis, stepped down as head of DeepMind to focus on drug discovery; he now serves as DeepMind's chairman. Hassabis and John Jumper, then a DeepMind director, won the Nobel Prize in chemistry for the lab's work on AlphaFold.
Isomorphic Labs did not disclose its new valuation. Bloomberg reported earlier this month that the company was looking to raise funding at a $50 billion valuation.


